M G Nikolaeva1,2, A P Momot3,4, M S Zainulina5,6, N N Yasafova7, I A Taranenko7. 1. Altai Branch of FSBI "National Research Center for Hematology", Barnaul, Russia. nikolmg@yandex.ru. 2. FSBEI of Higher Education "Altai State Medical University", 40 Lenina Ave, Barnaul, 656038, Russia. nikolmg@yandex.ru. 3. Altai Branch of FSBI "National Research Center for Hematology", Barnaul, Russia. 4. FSBEI of Higher Education "Altai State Medical University", 40 Lenina Ave, Barnaul, 656038, Russia. 5. Saint Petersburg State-Financed Health Institution "Birth Centre № 6 named after Professor V.F. Snegireva", St Petersburg, Russia. 6. Obstetrics, Gynecology and Reproductive Medicine Department "Pavlov First Saint Petersburg State Medical University", St Petersburg, Russia. 7. Altai Regional Clinical Hospital, Barnaul, Russia.
Abstract
OBJECTIVE: To study the association between high activity of Factor II (prothrombin) in blood plasma with G20210A mutation and the development of great obstetrical syndromes. MATERIAL AND METHODS: A prospective clinical cohort study was conducted on 290 pregnant women (average age 31.7 ± 4.7 years old). The main group was made up of 140 G20210A patients, while the control group comprised 150 women with the wild G20210G type. The aim was to evaluate the activity of Factor II in the venous blood plasma during the stages of pregnancy with regard to trophoblast invasion waves. As per results, association analysis of Factor II activity value and gestational complications was carried out. RESULTS: In the control group, the median (Me) of Factor II activity ranged from 108% (preconception period) to 144% (pregnancy) [95% CI 130-150]. In patients with the GA type, the value was significantly higher in related periods, ranging from 149 to 181% [95% CI 142-195], p < 0.0001. With Factor II activity ranging from 148.5 to 180.6%, pregnancies in the main group had no complications. Higher levels of Factor II activity were associated with the development of early and/or severe preeclampsia (PE) and fetal growth retardation (FGR). CONCLUSION: The data obtained regarding Factor II activity in blood plasma, juxtaposed with the development of great obstetrical syndromes, allow to assume that manifestation of G20210A in early and/or severe PE and FGR is associated with this coagulation factor's level of activity. Threshold value of the Factor II activity with G20210A mutation, allowing to predict the development of PE, comprised 171.0% at the preconception stage (AUC - 0.86; p < 0.0001) and within 7-8 weeks of gestation it was 181.3% (AUC - 0.84; p < 0.0001).
OBJECTIVE: To study the association between high activity of Factor II (prothrombin) in blood plasma with G20210A mutation and the development of great obstetrical syndromes. MATERIAL AND METHODS: A prospective clinical cohort study was conducted on 290 pregnant women (average age 31.7 ± 4.7 years old). The main group was made up of 140 G20210Apatients, while the control group comprised 150 women with the wild G20210G type. The aim was to evaluate the activity of Factor II in the venous blood plasma during the stages of pregnancy with regard to trophoblast invasion waves. As per results, association analysis of Factor II activity value and gestational complications was carried out. RESULTS: In the control group, the median (Me) of Factor II activity ranged from 108% (preconception period) to 144% (pregnancy) [95% CI 130-150]. In patients with the GA type, the value was significantly higher in related periods, ranging from 149 to 181% [95% CI 142-195], p < 0.0001. With Factor II activity ranging from 148.5 to 180.6%, pregnancies in the main group had no complications. Higher levels of Factor II activity were associated with the development of early and/or severe preeclampsia (PE) and fetal growth retardation (FGR). CONCLUSION: The data obtained regarding Factor II activity in blood plasma, juxtaposed with the development of great obstetrical syndromes, allow to assume that manifestation of G20210A in early and/or severe PE and FGR is associated with this coagulation factor's level of activity. Threshold value of the Factor II activity with G20210A mutation, allowing to predict the development of PE, comprised 171.0% at the preconception stage (AUC - 0.86; p < 0.0001) and within 7-8 weeks of gestation it was 181.3% (AUC - 0.84; p < 0.0001).
Authors: Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: A Zivelin; N Rosenberg; S Faier; N Kornbrot; H Peretz; C Mannhalter; M H Horellou; U Seligsohn Journal: Blood Date: 1998-08-15 Impact factor: 22.113
Authors: F R Rosendaal; C J Doggen; A Zivelin; V R Arruda; M Aiach; D S Siscovick; A Hillarp; H H Watzke; F Bernardi; A M Cumming; F E Preston; P H Reitsma Journal: Thromb Haemost Date: 1998-04 Impact factor: 5.249
Authors: U Nowak-Göttl; R Junker; W Kreuz; A von Eckardstein; A Kosch; N Nohe; R Schobess; S Ehrenforth Journal: Blood Date: 2001-02-15 Impact factor: 22.113
Authors: J Emmerich; F R Rosendaal; M Cattaneo; M Margaglione; V De Stefano; T Cumming; V Arruda; A Hillarp; J L Reny Journal: Thromb Haemost Date: 2001-09 Impact factor: 5.249
Authors: P A Kyrle; C Mannhalter; S Béguin; A Stümpflen; M Hirschl; A Weltermann; M Stain; B Brenner; W Speiser; I Pabinger; K Lechner; S Eichinger Journal: Arterioscler Thromb Vasc Biol Date: 1998-08 Impact factor: 8.311